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Abstract
Tibetan medicine is an ancient tradition, stretching back over one thousand years.
Today, the Tibetan medical community, centered at the Men-Tsee-Khang (Tibetan
Medical and Astrological Institute) in Dharamsala, India, is trying to bring Tibetan
medicine into the modern world. They are doing this mainly by focusing on research,
based on modern scientific methods, to produce clinical and laboratory studies
demonstrating the efficacy of Tibetan medicine. This paper compiles interviews from
Men-Tsee-Khang staff closest to these projects, articles about modernizing traditional
medicine from both the Tibetan and Western perspectives, and a review of some of the
recent studies to come out of Men-Tsee-Khang. The overall goal is to see how Tibetan
medicine is hoping and trying to situate itself within the modern scientific and medical
community and evaluate the possible outcomes of these actions.
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Introduction
Tibetan medicine is a tradition stretching back in history for over a thousand
years. According to legend, the tradition dates back as far as the 2nd century C.E. but it
was officially codified starting in the 7th century C.E. The main texts, including the
rGyud zhi, were recorded in their current form in the 13th century. 1 Despite its ancient
roots and strong ties to Buddhist philosophy, Tibetan medicine is now trying to prove
itself to the world and become recognized as successful and useful medical system.
Tibetan medicine, its practitioners, and researchers have an interesting path ahead
of them: to situate the system as a respected member of the modern medical and scientific
community, while maintaining their traditional values. They have learned from the
experiences of other traditions such as Ayurveda and Traditional Chinese Medicine
which, in the name of advancement, have lost much of the traditional theory and practice
that made them so unique. 2 In the words of Dr. Thokmay Paljor, editor of sMan-rTsis
Journal: “I feel, more research work on Tibetan medicine, particularly with regards to
clinical research needs to be done scientifically, but at the same time our traditional basic
values must be maintained intact.” 3 This is a thin line to walk but Men-Tsee-Khang
seems determined to push through. To be successful and maintain its integrity, Tibetan
medicine must proceed carefully on this path, being aware of the many threats that it will
face from the outside world.
The Tibetan Paradigm
Tibetan medicine is a complete holistic medical system combining empirically
attained knowledge and Buddhist philosophy. This system has its own unique methods of
diagnosis, descriptions of disorders, and treatment plans. In Tibetan medicine, the health
of the body depends on the proper balance of the three humors, or nyes pa: rlung, mkrhis
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pa, and bad kan. 4 Each person has a specific combination of these humors, which is
believed to effect his or her constitution, or personality. 5 Certain factors such as emotions
of ignorance, desire, and hatred, poor diet, seasonal changes, and karma accumulated in
past lives can affect the balance of these humors leading to specific diseases 6 .
This holistic approach to disease calls for an equally holistic set of treatments,
which focus on repairing the humoral balance of the body, instead of treating one specific
body system. These treatments are multi-faceted and can include Buddhist counseling
and practice, dietary and behavioral counseling, external manipulations (moxibustion,
acupuncture, massage), and drug regimens. 7 Tibetan drugs comprise an important part of
most treatments and are compounded from natural ingredients including herbs, minerals,
and animal products. They are produced in accordance to traditional texts and “designed
to simultaneously treat disorders, restore balance, and control side-effects.” 8 These drugs
tend to be slow acting but have little or no side effects. Another important aspect of
holistic treatment is the ever-compassionate and humanitarian nature of patient treatment,
including patient-doctor interactions and the fact that Men-Tsee-Khang is a non-profit
organization providing treatment to all in need at little or no cost. According to one
physician, this is the most unique and important aspect of Tibetan medicine. 9
While there has been little official research done on Tibetan medicine, the system
has been in use for so long that doctors have had a chance to observe which treatments
are the most effective and thus refine their practice through informal, ongoing research.
While biomedical research may be a relatively recent phenomenon, Tibetan medicine’s
“test of time is counted in centuries.” 10 Many of my interviewees mentioned this history
of observational research and said that research is not a new concept in Tibetan medicine.
4
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Dr. Dadon, head of Research and Development at Men-Tsee-Khang, said that the main
differences between the historic research and the current clinical trials are the
methodologies and documentation which are necessary for acceptance in the scientific
community. 11 Tibetan medicine also has a history of collaboration with other medical
systems starting in the 7th and 8th centuries C.E. with dialogues between Tibetan, Persian,
Greek, and Nepalese physicians. 12 According to Tsultrim Kalsang, a Tibetan physician
and botanical specialist, these early interactions with other medical systems have set a
precedent for ongoing collaboration. 13
Comparisons to the West
There are many names used to refer to the modern medicine centered in the West
with varying connotations. These include Western medicine, modern medicine, allopathic
medicine, and biomedicine. For the purpose of this paper, I will mainly be using the term
biomedicine because of the theoretical and scientific implications of the term. For the
issues I will be discussing, this term seems to best represent the opposing medical
paradigm. 14
As compared to Tibetan medicine, biomedicine is “mechanistic and reductive in
its approach to health and disease and is primarily based on the doctrine of single
causation and above all on the germ theory.”15 Modern science and biomedicine tend to
focus on individual aspects of health such as certain diseased organs, single ingredient
drugs, and single causes of disease. 16 The biomedical concepts of body and health are
based almost exclusively on empirically derived scientific data and lack any spiritual
component. In his comparison of the two systems, Peter Fenton states, “The notion of
spirit as a health transforming agent is conspicuously absent from modern medical
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practice.” 17 Biomedicine has developed, at least recently, hand-in-hand with scientific
research focused on both the causative agents of disease (bacteria, viruses, and genetic
pre-dispositions) and on the extensive laboratory and clinical testing of new drugs.
Biomedicine has also become extremely commoditized and commercialized, lending it a
very different ethos from Tibetan medicine.
Perceptions of Each Other
According to Eliot Tokar, an American practitioner of Tibetan medicine, the West
has a very shallow understanding of Tibetan medicine due to a “lack of sophistication by
the majority of biomedical and scientific personnel regarding traditional medicine from
either an epistemological, historical, medical, nosological, or other pertinent
perspective.” 18 While the biomedical and scientific community may recognize the value
of certain Tibetan treatments, they view these as a cache to be mined and put to use for
their own benefit. There is little consideration of the whole system. Many Tibetan doctors
believe that Tibetan medicine has gained interest from science and biomedicine because
of its success in treating certain chronic, hard to treat diseases very successfully. 19 Dr.
Namgyal Tsering believes that while the West may be interested, they are not very
knowledgeable about Tibetan medicine and do not yet trust it. 20 Furthermore, I fear that
this interest is motivated not out respect for Tibetan medicine, but out of more selfish
interests.
On the other hand, Tibetan medical practitioners seem to fully respect
biomedicine. Their only common criticism of the system is the high rate of side-effects
associated with many Western drugs. 21 They recognize that the drugs are powerful and
effective but say that biomedical doctors need to pay more attention to the body as a
whole, not as a collection of unrelated parts. 22 Tibetan physicians commonly praise
certain aspects of biomedical diagnosis: Dr. Yeshi Dorjee uses a sphygmomanometer to
17
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take more accurate blood pressure measurements 23 and Dr. Tsultrim Kalsang hopes that
Men-Tsee-Khang can get x-ray and MRI machines to assist with diagnosis. 24 The Tibetan
doctors and researchers I interviewed also tend to view biomedical research as the
standard of absolute knowledge, and the goal to which they should aspire. Dr. Namgyal
Tsering, deputy director of MTK, seemed adamant that Tibetan medicine must work
together with scientists to advance and that scientific evaluation of Tibetan medicine is
absolutely necessary, even though it has passed the test of time and is based on reliable
religious scriptures. 25

The Question of Recognition
Currently, Tibetan medicine is not an officially recognized healthcare system by
any government or organization. This lack of recognition has widespread ramifications
on both the practice and research of Tibetan medicine. According to Pema Thinley, “it
[Tibetan medicine] does not receive the institutional and official recognition that it needs
to carry out its humanitarian mission.” 26 This lack of recognition is commonly cited as a
motivation for further research showing the efficacy of Tibetan medical treatments. It is
thought that through scientific evidence, Tibetan medicine can gain the attention and
recognition it deserves in the worldwide medical and scientific community. 27
The current center of Tibetan medical practice is within the Tibetan exile
communities of India. Here, Tibetan medicine serves many Tibetans as well as Indians,
and foreigners in 53 Men-Tsee-Khang branch clinics. 28 India is home to a rich set of
traditional medical systems, including Ayurveda, Siddha, and Unani, and has a governing
body for such systems known as the Central Council of Indian Medicine (CCIM). 29 This
governing body has the ability to recognize Tibetan medicine as a viable health-care
system. By gaining membership to this council, Tibetan medicine would be regulated by
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the Indian government and would be eligible for government funding, especially for the
purpose of further clinical research. 30 Men-Tsee-Khang has long been lobbying this body
for recognition but has so far been unsuccessful. As of 1997, CCIM insisted that Tibetan
medicine is a branch of Ayurveda and refused to recognize it as anything other than
“Tibetan Ayurveda.” 31 However, according to Dr. Dadon, head of R&D at Men-TseeKhang, the Council recently sent a group of Ayurvedic doctors to Men-Tsee-Khang to
observe the similarities and differences between Tibetan medicine and their own system.
The group realized the vast difference between the systems and Dr. Dadon says she feels
confident about Tibetan medicine’s pending application to the Council. 32
While the process of government recognition in India seems as if it might soon be
resolved, other governments and organizations are still struggling with the issue. The
World Health Organization is beginning to investigate the potential of several traditional
medicine systems, including Tibetan medicine. They have developed a policy for the
investigation and integration of traditional medicine, the WHO Traditional Medicine
Strategy 2002-2005. 33 However, their website provides no further update on a new
strategy or progress since 2005. While there is no explicit mention of Tibetan medicine in
this policy, the WHO generally advocates increased research on efficacy and safety as
well as development of government policy on a nation-by-nation basis. They cite
increased global interest in traditional medicine, “Indeed, WHO member states are
increasingly and repeatedly requesting more assistance and guidance on TM/CAM
issues.” 34 Tibetan sources seem to think the WHO could be influential in the acceptance
and spread of Tibetan medicine. For example, esteemed Tibetan doctor Dr. Sonam
Wangdu Changbhar said, “It would be a lot easier if the WHO and the international
community recognized and accepted Tibetan medicine officially as an alternative
treatment and helped open permanent centers in different cities, so that people could avail
themselves of this unique natural system.” 35 While the WHO could prove instrumental in
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the spread of traditional medicine, including Tibetan medicine, especially to poor and
developing areas, they do not officially recognize it or any other system.
In the United States, Tibetan and other “alternative” medicines are handled
mainly by the National Institute of Health’s National Center for Complementary and
Alternative Medicine (NCCAM) and the Food and Drug Administration (FDA). 36 While
the FDA is purely a regulatory body, NCCAM is a research institution that works closely
with traditional medicines. The 2008 operating budget of NCCAM is $121,577,000
awarded in Congressional appropriations. 37 This shows a concerted effort by the
government of the United States to investigate alternative medicines, including Tibetan
medicine and is a potentially promising sign, although there are still many hurdles to
jump. The NCCAM’s mission is to “Explore complementary and alternative healing
practices in the context of rigorous science, train complementary and alternative medicine
researchers, and disseminate authoritative information to the public and professionals.” 38
While some Tibetan medicines are marketed in the U.S., it is as “herbal supplements” not
recognized medicines. The same is true with the practice of Tibetan medicine: while there
are practicing doctors, they are not recognized as healthcare worker but are generally
allowed to practice. However, “in the eyes o the law, practicing Tibetan medicine as
medicine in the USA is a crime.” 39 I feel that Dr. Namgyal Tsering described the
situation well: the government knows that Tibetan medicine is helpful in improving the
health of many patients, yet they will not officially recognize it. They view it with “one
eye open and one eye closed,” allowing some things to slip by while carefully regulating
others. 40 Adams describes it very similarly, adding the facet of economic pressures: the
US government keeps, “one eye on the market and the other on the definitions of safety,
truth and efficacy in the medical field.” 41

Research
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Research Goals of Tibetan medicine
The Tibetan medical community centered at Men-Tsee-Khang, Dharamsala,
India, is avidly pursuing research for the benefit of both the Tibetans they serve and
recognition by the larger medical and scientific community. Dr. Tsutrim Kalsang insists
that all research under-taken by Men-Tsee-Khang is “only for the human purpose, not to
spread Tibetan medicine.” He believes the main purpose is to solve health problems that
most affect their local Tibetan patients, and not to gain outside attention. 42 However,
most of my interviewees cite reasons such as the spread of Tibetan medicine and gaining
recognition as the main reasons for increased research. 43 In his introductory remarks, the
editor of the sMans-rTris Journal states its goals as follows:
[This represents] our sincere attempt to present some scientific research papers to
let the word community understand that an ancient Tibetan medical tradition has
all the potentials to meet all the standard requirements of a scientifically
acknowledged medical system of the world. 44
As mentioned earlier, many cite the need for international recognition as a reason for
scientific research on Tibetan medicine. According to Deputy Director Namgyal Tsering,
Tibetans know Tibetan medicine is effective because of its long, successful history and
basis in Buddhist scripture. However, scientific proof is necessary for the outside
world. 45
Goals of Outside Research
If you search “Tibetan medicine” on the PubMed database (largest database of
medical and scientific publications), you will come up with over 87 results, mostly
articles by Western or Chinese researchers. 46 By skimming the titles, one this is obvious:
the main difference between the research strategies of Men-Tsee-Khang and these other
institutions is that almost all of the Western and Chinese research is focused on single
42
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active ingredients and mechanisms of action, and not the overall effects of a treatment
regimen. This focus demonstrates a fundamental difference between the research pursued
by the two groups. Tibetan medicine is only interested in showing the efficacy of their
treatments, while biomedical research wants to know how the treatments work within the
confines of their medical paradigm. While this research can be purely for the progression
of scientific knowledge, it often has deeper motivations. These motivations, mainly
focusing around commercialization, can expose Tibetan medicine to multiple dangers, as
discussed later. Once an active ingredient is isolated and tested, it can be patented as a
biomedical-style drug and put into use in the Western pharmacopoeia. 47 Such research
seems focused on finding new active ingredients to be used in biomedical drugs, not for
the furthering of the Tibetan medical tradition as a whole.
Conflicts in Methodology
“The points of contestation are numerous, and frequently organized around
several basic questions: whose versions of medical efficacy are correct? Whose
terms of diagnosis are the most appropriate for clinical research? Are both
medical systems ‘scientific’? If so, how does one deliberate between different
claims of truth offered by each? If not, who determined the bounds of scientific
legitimacy?” 48
According to Dr. Steven Strauss, former director of the NCCAM, the “goldstandard” in biomedical clinical research is the randomized controlled clinical (RCC)
trial, preferably double-blind and with a placebo control. 49 In this experimental design,
the involved patients are informed of the possible treatments and then randomly assigned
into either the control or experimental group. In a double-blind, placebo controlled study,
the control group receives a non-active drug substitute (such as a sugar pill) and neither
the doctors evaluating the treatment nor the patients know whether they are receiving the
actual treatment or the placebo. 50 It is important that the sample size of participants is
large enough to provide statistically significant results. 51 This design works best to test the
47
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efficacy of a single type of treatment for a specific disease, although, as discussed later,
this can be modified somewhat.
While creating a clinical trial to test the efficacy and safety of Tibetan medicine,
may factors must be considered. Tibetan medicine is a completely different medical
paradigm with its own systems of diagnosis, prescription, and evaluation. Because of this,
it cannot always be manipulated and evaluated in the same ways as biomedicine, or at
least not fairly. According to Dr. Tokar: “If experimental studies are to be done to
determine safety and efficacy, research protocols must be specifically designed which are
appropriate for investigating the theory and practice of Tibetan medicine.” 52 There are
also many cultural concerns involving linguistic and conceptual translations when
performing a clinical trial in a non-Western setting. These issues are deep-rooted and
hard to solve. Adams states: “This sort of difference occurs at the level of epistemology
of basic assumptions about how we know, or establish, truth about medical efficacy.” 53
The first issue arising in the development of a clinical trial is determining the
disease to be investigated. Since there is rarely a one-to-one correlation between Tibetan
and biomedical diagnoses, one standard must be picked. 54 Because of their broader
recognition, biomedical diagnoses such as diabetes, Hepatitis B, or hypertension are
usually chosen for investigation. However, in Tibetan medicine, such a biomedical
diagnosis could cover a range of ailments caused by numerous different imbalances and
distant causes. The question then arises of which treatment plan to use. Under a normal
clinical setting, patients falling under such a biomedical diagnosis would be treated in
many different ways due to their individual constitutions and symptom presentation. 55
Tibetan treatment also commonly varies throughout the course of recovery, depending on
the progress of the patient. 56 This, as mentioned above, does not lend itself particularly
well to the RCT model which best examines a single drug treatment plan. A major risk
involved in the development of clinical trials is the over-simplification of diagnosis and
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treatment. If patients are diagnosed by biomedical doctors and all given the same
treatment that is used for certain presentations of a similar Tibetan disease, how
accurately does this measure the efficacy of the entire Tibetan medical system? The
choice of diagnostic and treatment standards is an important one with serious
ramifications. According to Adams: “Starting with biomedical diseases results in a
disorganization of the Tibetan approach, undermining the logic of its etiology and
treatment resources, and making it most likely that it will not produce statistically
successful outcomes.” 57
The next methodological issue facing Tibetan medicine clinical trials is
determining standards by which efficacy and success are judged. Once again, success is
generally judged by biomedical standards. As with choosing biomedical diagnoses, this
makes sense if the trial is to gain the attention of biomedical researchers but has
potentially dangerous consequences as well. This can best be demonstrated in an example
presented by Adams in “Randomized Controlled Crime.” A Western researcher
conducted a study on the digestive pathogen Helicobacter pylori at the Lhasa Men-TseeKhang. She worked with Tibetan physicians to find the equivalent diseases and
symptoms and then tested the success of the traditional treatment. The trial was a success
by Tibetan standards as the treatment alleviated all the symptoms. However, the
treatment did not completely eliminate the bacterium from the patients’ systems so was
considered a failure by biomedical standards. When she returned for follow-up research,
she was told “The research had already proven to be unsuccessful in demonstrating the
efficacy of Tibetan medicine.” The introduction of a new concept of efficacy, the HP
bacterial count, caused the Tibetan doctors involved begin to doubt their treatment even
though it had worked successfully, by their standards, for hundreds of years. 58 The
overarching question is what exactly is being tested: a particular Tibetan drug compound,
or the entire system of treatment from diagnosis to recovery. Just because a Tibetan
treatment does not alleviate certain biomedically recognized symptoms, does not mean
that the treatment could not be very useful to people around the world.
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Also, one must question what exactly is being tested and if, by taking a particular
treatment out of a complex system could contribute to the supposed lack of success. As
mentioned above, the simplification of diagnosis, treatment, and indicators of success can
greatly affect the outcome of a clinical trial. In their article, Loizzo, et al, introduce the
concept of “black box” research. In this method, only the original diagnosis and the final
outcome of the treatment are analyzed. This leaves the Tibetan physician to prescribe and
treat the patient according to his training, with no influence of the research system. 59
While this system does not provide the same controls as the RCC model, it allows for the
entire Tibetan medical system to be tested without interference. If this kind of research is
recognized by the world community, it is the perhaps the best opportunity for Tibetan
medicine to demonstrate its efficacy while maintaining its traditional nature.
When doing clinical trials in a new environment, there are many translation
related issues that must be considered. First, there must be sufficient linguistic translation
to ensure the proper communication between indigenous doctors, outside researchers, and
patients. This requires significant infrastructure and resources that may be unavailable
depending on the location of research. 60 Beyond simple linguistics, however, there are
many other cultural and conceptual translations that must be successfully accomplished
as well. In order to comply with ethical standards, researchers must gain informed
consent from the participants. “Informed” includes a full understanding of the risks
involved with both receiving and not receiving the experimental treatment and familiarity
with the process of randomization. In an example provided by Adams in “The Challenge
of Cross-Cultural Clinical Trials Research,” both of these topics caused a problem. First,
Tibetans tend to believe that if bad possibilities (such as potential side-effects) are
discussed, they are far more likely to happen. Thus patients were unwilling to listen to the
potential risks of participation in the trial. 61 Secondly, complete random chance is not a
familiar concept in Tibetan society where karma is seen as the cause for future events.
Thus patients tend to assume a karmic cause for their placement in either the control or
experimental group. To solve logistical problems of this nature, researchers must look
59
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deep into the culture in question to find similar concepts. For example, in American
culture, randomization could be described a flipping a coin, however, concept does not
exist in other cultures so a similar but culturally relevant example must be found. 62
Men-Tsee-Khang as a Research Institution
Mission
Over the past few years, Men-Tsee-Khang has produced a number of clinical and
laboratory studies. The greatest collection of this research is the sMan-rTsis Journal
published in August 2007. 63 Here I will review and analyze some of the research
presented in this and other sources to evaluate the current standing of Tibetan medical
research.
Review of Research
The use of mercury in many traditional medical traditions is one factor that has
slowed the incorporation of Tibetan medicine and other traditions into mainstream
Western use. Tibetan medicine uses a highly processed form of mercury known as tsothel
and claims that in this form, the mineral is non-toxic. In this small study, “Mercury in
Traditional Tibetan Medicine: panacea or problem?” they try to demonstrate that the use
of mercury is not harmful. The clinical research took place at Delek Hospital,
Dharamsala, while the laboratory analysis was performed by consulting researchers in
Israel. The study compares two experimental groups (one taking mercury-containing
precious pills and one taking non-mercury-containing precious pills) and one control
group (taking no Tibetan medicine) for an average range of 24-51 months exposure. The
patients were tested for traces of mercury in blood and urine and examined for signs of
mercury toxicity. 64 The study was partially blind, but not double blind and the groups
were poorly randomized. Also, with group sizes ranging from two to six, the sample size
62

Ibid, p. 279-280.
sMan-rTsis Journal (Journal of Tibetan Medicine & Astrological Science) Vol. IV Issue 1 August 2007
64
Sarah Sallon, Tenzin Namdul, Sonam Dolma, Pema Dorjee, Dawa Dolma, Tseten D. Sadntshang, Pnina
Ever-Hadani, Tali Bdolah-Abram, Steven Apter, Shlomo Almog. “Mercury in Traditional Tibetan
Medicine- panacea or problem?” sMan-rTsis Journal: Vol IV, Issue 1, August 2007.
63

17

is far too low for statistical conclusiveness. The preliminary results suggest that the
mercury is not absorbed by the body and has no toxic effects but, due to above mentioned
issues, these findings are not conclusive and will do little to convince the Western
skeptics.
The study “Clinical Trial of a Tibetan Medicine in the Treatment of Chronic
Hepatitis B,” is definitely a step in the right direction with 50 clinical participants and
fully randomized groups, double-blind methods, and thorough statistical analysis. 65 The
two large issues of this study are the seeming lack of a control or placebo group and no
explanation of the differences between the two experimental groups, only their titles:
Specific Tibetan Medicine and Traditional Tibetan Medicine. The former is inexcusable
in any scientific study as a baseline for comparison is critical. The patients were
compared only against their initial presentation with the issues of possible natural
variation of symptoms over time or the placebo effect being completely ignored. The
latter issue could simply have been lost in translation and maybe these two terms are
descriptive enough to certain audiences but when the goal is to draw the attention of the
wider community, such things must be fully explained. The other main issue plaguing
this study is the general lack of presentation skills, especially when dealing with the
statistics. Overall the English was poor and the manuscript appeared unedited. As for the
statistics, they were performed by a trained statistician and appeared thorough and helpful
but the authors did not seem to understand the statistical results and therefore the power
of such analysis was completely lost. While this clinical trial is an improvement, MenTsee-Khang researchers need to keep their intended audience in mind because even if the
hard science is there, it won’t be recognized if its hidden under poor writing and lack of
thorough explanation.
Other examples of recent or ongoing research include and observational study on
cancer treatment and a survey of blood pressure throughout the Tibetan exile community.
The observational study follows the treatment of 640 cancer patients at various MenTsee-Khang clinics across India for a period of three years. General conclusions of
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effectiveness are made but no statistical analysis is presented to support these claims. The
study itself states that it is not controlled or standardized, but purely observational. 66
Except for the more extensive records kept, this study is not particularly different from
the continuous observational research that has been going on for centuries. This kind of
research lends nothing to the progress of Tibetan medicine in the eyes of the world. The
other study mentioned, was a simple preliminary survey of blood pressure of all Tibetans
in India between the ages of 32 and 70. While this in itself does not demonstrate the
efficacy of Tibetan medicine, it is hoped that the high rates of hypertension discovered
will encourage a clinical investigation into Tibetan treatments for this disease. Dr. Dadon,
the head of the Clinical Research Department, hopes that a hypertension study will be the
next extensive project undertaken by the department. 67
A Good Example
A stronger example of Men-Tsee-Khang’s recent research can be found in
“Efficacy of Tibetan Medicine in the Treatment of Type 2 Diabetes Mellitus
(NIDDM).” 68 This study evaluates the progress of 200 patients over the period of 24
weeks and compares two completely randomized groups: one receiving Tibetan medicine
and making dietary and lifestyle changes, the other only making the diet and lifestyle
changes. The diet and behavioral recommendations were base on those from the
American Diabetes Association, showing an interesting synthesis of the two systems.
Also, instead of doing a single-drug study, this is a multi-drug study where each patient
was diagnoses by a Tibetan doctor and prescribed a combination of four drugs based on
specific humoral imbalances. This shows that the traditional diagnostic practices can be
maintained even in the context of a clinical trial, helping to preserve the identity of
Tibetan medicine. This study has a large enough sample size and long enough duration to
provide substantial results that were successfully analyzed statistically. Unlike other
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trials, these statistical results were clearly reported. The only thing lacking was either a
double-blind experimental design or a placebo control. The patients showed better
improvement with Tibetan medicine than has been documented with biomedicine, with
an increase in blood hemoglobin count as the trial progressed. 69 The results of this study
were actually published as a letter in the American journal Diabetes Care, showing the
success of this study by modern scientific standards. 70
This is a strong example of how a clinical study can incorporate the entire
diagnostic and treatment methods of Tibetan medicine while maintaining the elements of
respectable, publishable scientific research. This demonstrates how science can be used
to support Tibetan medicine without oversimplifying it and without exposing it to
exploitation. This is a good application of Loizzo, et al’s “black box” methodology
described earlier. 71 In my opinion, this research model is the most promising for the
recognition of Tibetan medicine as an effective alternative medical paradigm.
So, where do they stand?
While these studies show an enthusiastic start to the process of incorporating
modern clinical and laboratory research, I believe the majority of them fall short of their
larger goals. Few of Men-Tsee-Khang’s employees are actually trained in the methods of
scientific research and it shows. Currently, all the members of the Clinical Research
department are trained Tibetan physicians and Men-Tsee-Khang relies on All India
Institute of Medicine (AIIMS) to help plan the clinical trials and analyze the data. 72 The
institution needs to focus on recruiting such trained specialists to work in conjunction
with the traditionally trained staff. This would greatly increase the power and ability of
their research teams. Until then, I think their teams could benefit from slowing down and
working on larger-scale, better designed trials and studies instead of many small
preliminary experiments. While each large study would be more of a monetary and time
investment, they would go far further in establishing Men-Tsee-Khang as a reputable
69
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research institution. Another important goal is to seek publication in peer-reviewed
journals: the standard of scientific literature. 73 While internal journals such as sMan-rTsis
Journal provide a means of publication, they serve little use as far as gaining acceptance
in the wider community.
The main issues currently holding Men-Tsee-Khang back are funding and
approval. Currently studies are funded from many sources including internal funding
from the institute and from various private sources. These private sources range from
individuals to larger organizations and are both domestic and foreign in source. 74 Dr.
Dadon hopes that CCIM will soon recognize Tibetan medicine, opening the door the
government funding. 75 Once Men-Tsee-Khang can establish itself as a reputable research
institution, it may also be eligible for research grants by organizations of the WHO. 76
Also, the process of approval by ethical committees can further slow the progress of
research. All proposals must first be approved by Men-Tsee-Khang’s ethics committee
and then by the ethics committees of any other participating institutions. Currently, the
department is waiting indefinitely for an ovarian cancer proposal to be approved by
AIIMS. 77 Because of the methodological challenges presented earlier, the process of
ethical approval can be long and arduous. 78

Tibetan Medicine in the Global Community
According to Dr. Eliot Tokar, the last decade has brought “a new openness by
scholarly institutions, hospitals, physicians, and medical schools” regarding Tibetan
medicine. 79 While global interest in Tibetan medicine is growing quickly, the entire
system, with its complex methodologies and beliefs, cannot be immediately transferred
from one culture and place to another without careful consideration of many complicated
issues. Questions arise as to what aspects of Tibetan medicine should be incorporated into
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global healthcare, who should practice such procedures, from where the raw materials for
drug production will come, and the types of regulation that are necessary. Great care must
be taken when considering these issues because of what is at stake. “The economy of
time and commerce and the influence of the allopathic medical approach place the more
classical and holistic approach to Tibetan medicine at risk of being lost.” 80 It is also
important to keep in mind that these issues are not specific to Tibetan medicine but are
similar to those faces by all traditional and alternative medicine systems.
Despite these many issues, there is much promise for the potential contribution of
Tibetan medicine to world health. Perhaps the most promising potential application of
Tibetan medicine is to improving healthcare in poor and developing areas where
biomedicine is unaffordable and the diagnostic technologies so heavily relied upon are
unavailable. 81 This type of humanitarian work fits well with the goal main goal of
Tibetan medicine: to alleviate the suffering of all sentient beings. Many of my informants
also cited Tibetan medicine’s potential for treating many chronic and hard to cure
diseases. 82 Dr. Tokar also believes that the holistic understanding of health propagated by
Tibetan medicine could raise awareness of the interconnected nature of health and help
people world-wide live healthier daily lives. 83
Medical Pluralism vs. Selective Incorporation
A major question in the globalization of Tibetan medicine is to what extent the
system will spread. Will it continue to be practiced in its entirety or will convenient
aspects break off from the system and be incorporated into the existing medical
paradigm?
The idea of medical pluralism is the acceptance that more than one successful and
reputable medical paradigm exists. From this perspective, Tibetan medicine and
biomedicine are viewed as completely and fundamentally different, yet neither is judged
as superior. In such a system, “ancient medical traditions are allowed to preserve their
80
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disciplines intact, while continuing to develop to meet evolving public health
circumstances.” 84 Medical pluralism would require both official recognition and
widespread respect for all medical systems involved, including Tibetan medicine. Within
such a framework, Tibetan medicine would be left unrestricted to practice as long as
treatments remained successful. 85 For Tibetan medicine to be practiced to its full extent
and maintain its maximal effect, it must be accepted as a unique but equally valid medical
system. Without this acceptance, Tibetan medicine will be under a lot of pressure to
modify its practices to fit in with the single existing biomedical paradigm causing
degradation in the traditional character of the treatments. Tibetan medicine's best chance
of spreading and flourishing intact around the world is within such an epistemological
framework.
The other, perhaps more likely, mechanism of spread is through the selective
incorporation of specific Tibetan medical treatments into biomedicine after they are
proven effective through extensive research. Currently in India, there is a lot of joint
treatment with Tibetan medicine used to supplement biomedical treatments. The most
common use of such supplementation is Tibetan medicine being used to counteract the
side-effects of intensive biomedical treatments such as those for tuberculosis and cancer.
When a biomedical doctor thinks such a supplementary treatment would be beneficial to
the patient, he refers him to a Tibetan doctor for treatment.86 This system works well in
India because of the easy access to both types of treatment and the ease of
communication between the doctors of the different fields. However, the lack of trained
Tibetan medical practitioners in the West would likely lead to biomedical doctors trying
to prescribe Tibetan drugs without the proper consultation. Dr. Yeshi Dorjee insists that
anyone using Tibetan medicine should at least consult a pharmacist who has received
training on the Tibetan pharmacopoeia, if not a fully trained physician. 87 This, like the
issue of fraud discussed later on, threatens to undermine the respectability of Tibetan
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medicine through improper use of Tibetan remedies. The marketing of Tibetan medicine
through pharmaceutical companies, as also discussed later, further increases the chance
that Tibetan treatments will simply be incorporated and prescribed as if they were new
biomedical drugs. While drugs are a large and effective aspect of the Tibetan system,
their use out of context undermines the entire essence of the holistic Tibetan system.
Regulatory Issues
Most developed countries already have extensive regulatory frameworks in place
for the approval of drugs and the practice of medicine.88 However, these regulatory
structures are fashioned around the biomedical paradigm and do not always conform
easily or ethically to Tibetan medicine.
Without extensive testing and regulation, Tibetan medicines can currently be
marketed in the US as health food or nutritional supplements. Upon arrival on the market,
these must be tested, screened, identified, and shown to be safe. 89 While most Tibetan
drugs would pass these initial regulatory tests, to be respected and considered as
medicine, much more extensive tests must be undertaken. 90 This scenario establishes
somewhat of a double jeopardy situation for Tibetan medicine: medicines are relegated to
supplement status unless full tested, however, with this testing they run a high risk of no
significant results (due partially to methodological issues discussed earlier). If, in this
testing, drugs show no medical benefit, they will not be further considered as a medicine
and will likely be pulled from the shelf as supplements as well.
Also, regulatory questions abound around the issue of belief or magic. While
these aspects of Tibetan medicine cannot be scientifically tested, they are an important
part of the traditional Tibetan medical practice, but also play a large role in its
marketability. As Adams states, “money is where the magic is,” with this extra
dimension adding to consumer appeal. 91 However, it is these aspects that cannot be easily
regulated and threaten to plunge all of Tibetan medicine into the hole of superstition and
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fraudulent practices. The current goal of government regulation is to protect patients from
being sold “magic” and being convinced it is medicine, compelling the state to “issue
laws that will protect citizens from their own beliefs.” 92
In order to establish a regulatory system that fairly evaluates Tibetan medicine
while protecting it from threats of fraud, governments and regulatory agencies must
develop systems of evaluation based on the concept of medical pluralism with its
underlying acceptance of multiple medical paradigms. Without such a concession,
Tibetan medicine and other traditional medical systems cannot be fairly and ethically
regulated to protect both their intrinsic values and the health and well-being of patients.
Legal and Ethical Issues
There are many legal and ethical issues relating to the global practice of Tibetan
medicine. The cultural differences between the Tibetan community in which the tradition
developed and is now practiced, and the various cultures to which it might spread, make a
direct transition difficult.93 The difference between the cultural contexts is perhaps the
highly commercialized and commoditized nature of biomedicine today. The biggest
perpetrators of this capitalist medical culture are the large pharmaceutical companies, or
Big Pharma. 94 These companies are beginning to take interest in Tibetan and other
traditional medicines and a trove of potential products and profits. Adams states,
“Pharmaceutical interests speak in languages of medical science as they cross geographic,
political, and cultural borders in order to pursue profits.” 95
The largest threat facing Tibetan medicine is the threat of commercialization by
exploitive pharmaceutical companies as part of the growing “Neutriceutical industry.” 96
The co-opting of traditional Tibetan remedies by the corporate sector leads to many
ethical issues. The standard of practice by pharmaceutical research is to identify new drug
compounds, test them, and once shown effective, patent them. By patenting a drug, the
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company in effect owns it and has exclusive rights to its production. As is the case with
biomedical drugs, these can then be sold at high prices with a large profit margin. This
can be viewed as “biopiracy” or intellectual theft since the idea is commandeered from
the Tibetan medical tradition and used for the profit of the company. If a company is
found guilty of biopiracy, they risk the loss of patents and profits, however, regulatory
agencies tend to turn a blind eye. 97 This issue threatens Tibetan medicine from many
different angles.
First, it introduces commercialization to Tibetan medicine. By patenting and
marketing Tibetan treatments, pharmaceutical companies can turn Tibetan medicine into
a commercial enterprise similar to biomedicine, potentially undermining the most
important aspects of Tibetan medicine. According to Dr. Tsultrim Kalsang,
commercialization goes against the Tibetan medical code of ethics for healing people. 98
Treatments should be affordable and available to everyone in need and, according to Dr.
Namgyal Tsering, the traditional scriptures forbid Tibetan medical professionals from
making a profit through their practice. 99 Both stressed this non-profit nature of Tibetan
medicine as being very important because of it is commercialization undermines the
Buddhist ethic and potential threatens other spiritual aspects as well. The introduction of
Tibetan medicine to the capitalist market also threatens the nature of patient-doctor
relationships which are traditionally based on absolute compassion and altruism. 100 These
relationships are particularly important to the treatment of conditions involving extensive
counseling, such as neurological and psychological problems. 101 If the people and
companies providing Tibetan medicine and care are making a profit, how altruistic are
they?
The patenting of Tibetan medical products could create a monopoly of
production, allowing the pharmaceutical companies to charge exorbitant prices. This
would in turn limit the access to Tibetan medicine where it is already practiced and
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prevent the spread to areas which most need the low cost, humanitarian system. 102 It is
ethically questionable enough to co-opt Tibetan medicine for profit while the traditional
practitioners are left uncompensated, but to then also limit the access of indigenous
populations is abominable.
Other Risks and Considerations
While the issues discussed above are perhaps the most pressing, many other
logistical issues also exist if Tibetan medicine is spread around the world. The spread and
increase in popularity of Tibetan medicine could have detrimental effects on the fragile
Himalayan environment if not carefully considered and controlled. Many plants and
natural products of the Tibetan pharmacopoeia are already limited to certain protected
areas in the Indian Himalayas. 103 Not only are some of them rare and endangered, but in
many cases, state governments tightly restrict and limit their harvesting. This raises the
question of how an increased demand for such products would be handled. Men-TseeKhang has started a project of small scale herbarium cultivation for the most rare and
hard to obtain plants. 104 Such a project would have to be greatly expanded to satisfy the
needs of a global Tibetan medicine market. Another possible solution is the substitution
of other related plants for the original Himalayan species. This process would obviously
have to involve careful investigation and testing by qualified Tibetan medicine-trained
personnel. 105 Some plants, however, may not be able to be cultivated outside their
environment or replaced by other species, posing the problem that maybe only part of the
traditional Tibetan pharmacopoeia could be marketed on a large scale. The biggest
related consideration is that small supply and high demand could drive drug prices up,
making them unaffordable to many patients who now benefit from their low cost. 106
Tibetan medicine cannot globalize only to leave those originally dependent on its care,
without access.

102

Interview: Eliot Tokar, email, 2 May 2008.
Pema Thinley, 1997, p. 17.
104
Interview: Dr. Tsultrim Kalsang, Men-Tsee-Khang, 19 May 2008.
105
Schwabl, 1998, p. 15.
106
Interview: Dr. Yeshi Dorjee, McLeod Ganj MTK Branch Clinic, 2 May 2008.
103

27

Another issue to consider is the possibility that demand for Tibetan medicine
practitioners will exceed the number of appropriately trained doctors. Dr. Yeshi Dorjee
predicted that with a rise in interest in Tibetan medicine, the number of fraudulent
practitioners will also increase. Since the system will be unfamiliar to many patients, it
will be easier to fool them. He believes that this is an inevitable issue with any alternative
medicine system but could tarnish the credibility to Tibetan medicine. 107 Men-TseeKhang is hoping to avert this problem by offering more extensive training opportunities
to foreigners in the near future by relocating and expanding their medical college. There
would then be many more slots for foreigners to undergo the full 5 year long course of
study. Also, Men-Tsee-Khang is working to translate all of the major texts into English
which will greatly help with the education of foreign practitioners of Tibetan medicine. 108
All of these issues and more must be carefully considered by Tibetan medical
researchers and practitioners around the world. If Tibetan medicine is going to become a
globally recognized and used form of treatment, development must proceed carefully
with special attention on issues of commercialization, intellectual theft, and fair
regulation. Without these precautions, Tibetan medicine stands to loose much of its
fundamental essence, and perhaps even be lost to those who currently depend on it.

A Disturbing Naivety
Throughout my interviews, I was continuously struck by how unconcerned most
Tibetan doctors seemed about the threats that I have discussed here. This is perhaps
because they are somewhat sheltered from the realities of the biomedical and
pharmaceutical industries. They sincerely hope Tibetan medicine can spread and relieve
the suffering of the global community and remain optimistic about such possibilities.
This is not to say that they are completely unaware of the potential risks, but more that
they seem to not fully grasp the scale of these risks and the detrimental effects they could
have on the continued existence and practice of Tibetan medicine.
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Most of my interviewees were able to cite at least on potential risk involved in
either continued research or the spread of Tibetan medicine. Dr. Tsultrim Kalsang
enthusiastically discussed the threat of commercialization in the West but was mainly
concerned about the loss of the altruistic doctor-patient relationship and spiritual
elements, not with the bigger issues of patents, biopiracy, or loss of access to Tibetan
medicine by the Tibetan community. 109 Dr. Yeshi Dorjee cited issues of fraud and the
proper training of Tibetan physicians abroad. 110 Dr. Namgyal Tsering mentioned the
possibility of commercialization and its negative impact on patients, but later stated that
there are no risks to continuing research and spreading Tibetan medicine. He believes that
research can only support what is traditionally known about Tibetan medicine. 111
I sincerely hope that much of this seeming naivety was because I was simply
asking the wrong questions. I tried to ask repeatedly about potential risks when I didn’t
get answers, even suggesting possible answers to some interviewees but still got little.
While language and translation could have contributed to the lack of responses, I fear that
this represents an actual and wide-spread trend. Through email correspondence with Dr.
Eliot Tokar, an American practitioner of Tibetan medicine and a scholar focused on such
issues, he mentioned that a similar naivety exists in the US:
Given that Prime Minister Samdhong Rinpoche has spoke out against the
commodification of Tibetan medicine -- as did the old teachers like Trogawa
Rinpoche and Tenzin Choedrak -- and that India is a land where the issue of
biopiracy is understood I have wondered why the younger Men-Tsee-Khang
amchis one meets in America these days are not more cognizant of this issue. 112
Through this research, I hope to gain the attention of the Tibetan medical and
research community and encourage them to further explore the potential threats facing
their field. While I believe that research and attempts to spread Tibetan medicine can be
successful for all involved, without knowledge of the potential risks, Tibetan medicine
leaves itself exposed to exploitive corporations and the biomedical market threatening its
continued existence.
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Conclusion
The topic of Tibetan medical research and expansion is a difficult and multifaceted issue. While I do believe that some good can come out of research initiatives, I
believe researchers should proceed with great care. Before a study is undertaken, the
methodology must be carefully considered to ensure that it gives the treatment in
question a fair chance of success. I feel that clinical trails that oversimplify Tibetan
diagnosis and treatment do not give such treatments a just chance of showing statistical
significance by biomedical standards. Alternatives to the randomized controlled clinical
trial such as the idea of “black-box” research need to be developed so that Tibetan
medicine is not forced to fit into the biomedical model. While research to identify active
ingredients and determine their pathways of action can add greatly to scientific
knowledge, they must be pursued with care and not used for the exploitation of Tibetan
medicine.
As for the globalization of Tibetan medicine, I agree with many of my
interviewees that it can help alleviate suffering around the world. However, as with
research, much care must be taken. For the greatest benefit to humanity, Tibetan
medicine must remain non-commercial and in the hands of trained Tibetan medical
professionals. All involved should take steps to prevent the usurpation of the rich
knowledge of Tibetan medicine by pharmaceutical companies. There are international
treaties against biopiracy, so if recognized, the Tibetan medical community can prevent
the patenting of their unique knowledge by others.
While this research is far from a complete analysis of this complex issue, I hope
that it serves to raise awareness within the Tibetan medical community. Tibetan medicine
is such a vast and valuable field, that I would hate to see it be negatively effected by the
increasingly interconnected and commercialized world. Tibetan medicine has too much
to offer to be lost forever in the throes of capitalism and the biomedical paradigm.
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Methodology
This research was carried out through a combination of interviews and textual
research. My interviews were conducted mostly at Men-Tsee-Khang, Gangchen
Kyishong, Dharamsala, India. One interview was conducted at the McLeod Ganj MTK
Branch Clinic and one was conducted via email. All interviews were conducted in
English as my informants all had a good grasp of the language. However, it is still
possible that some was lost in the language barrier. Interviews comprised the majority of
my field work as there were not any clinical studies or laboratory research in progress at
the time. I was hoping to observe and participate in some laboratory research at MenTsee-Khang during the ISP period, however, the research department was in the process
of moving to a new lab and neither lab was operational at the time.
I had some difficulties with interviews as most people insisted they did not know
enough about my topic of research and told me to talk to the “experts,” with whom I’d
already spoken. Also, as already discussed, even the “experts” seemed unfamiliar with
some of the topics of my interview. While this made research frustrating, it was a telling
indicator of the current Tibetan medical perspective of their research initiatives. I got
similar opinions from most of my interviewees which I do not think is fully
representative of the Tibetan medical community. In a brief conversation with the MTK
director, Dr. Dawa, he mentioned that extreme caution was needed in pursuing research
and other modernization initiatives. However, I was unable to meet with him later for a
formal interview due to his generally busy schedule and an emergency trip to Delhi. Also,
in my email correspondence with Dr. Eliot Tokar, he mentioned that many of the older
generation of teachers had spoken out against such efforts but I was unable to contact any
of those people or find textual sources to support that.
To fully develop this topic, much more background reading on the philosophical
and epistemological issues discussed would have been helpful as well as more field
research and interactions with members of both the Tibetan and biomedical communities.
Much more field research would be necessary to gain a full understanding of the diverse
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opinions relating to scientific research of Tibetan medicine. These things were simply not
possible with the time and resource constraints of the ISP.
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Future Research
I personally hope to return to Men-Tsee-Khang within the next few years to act as
some-what of a liaison between Tibetan medicine and scientific research. Men-TseeKhang is in the process of moving to a new, larger and better equipped laboratory. In this
new facility, they hope to greatly expand their laboratory research and seem to think that,
with my experience in laboratory research, I could be helpful in getting some projects off
the ground. After all Men-Tsee-Khang has done in helping me with this research, I would
love to give back in such a way.
As for other students, if you are scientifically inclined and have some lab
experience, it seems as if Men-Tsee-Khang would appreciate any help that you could
give and this would make for a fascinating and unique ISP. If you are interested in
Tibetan medicine but come from an economics or sociology background, a more
thorough investigation into the issues of globalizing Tibetan medicine would be very
interesting.
In general, Tibetan medicine is a fascinating and complex topic that I would
highly recommend investigating in some regard. I would just recommend caution because
within such a complex system, an even seemingly specific topic can become extensive
and tedious.

33

Glossary
bad kan (

)- the phlegm humor

biopiracy- negative term used for the appropriation of legal rights to indigenous
biomedical knowledge, usually through patents
mkrhis pa (

)- the bile humor

TM/CAM- traditional medicine/complementary and alternative medicine
tsothel (

)- the form of mercury used in Tibetan medicine,

“detoxified” through a complex process taking several months
nosological- a systematic arrangement, or classification, of diseases
nyes pa (
rlung (
rGyud zhi (

)- the three humors in Tibetan medicine
)- the wind humor
)- The Four Tantras, the central text in Tibetan

medicine
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India
Dr. DekyiInterviewed 24 April 2008, Tibetan Physician, Branch Clinic, Men-Tsee-Khang,
Dharamsala, India
Dr. DadonInterviewed 24 April 2008, Head of Research and Development Department,
Men-Tsee-Khang, Dharamsala, India
Dr. Yeshi DorjeeInterviewed 2 May 2008, Chief medical officer, Men-Tsee-Khang Branch Clinic,
McLeod Ganj, India
Dr. Eliot TokarInterviewed via email 3 May 2008, Tibetan physician, New York, NY, USA
Dr. Namgyal TseringInterviewed 5 May 2008, Deputy Director, Men-Tsee-Khang, Dharamsala, India
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